Chiho Fukiage

Senju Pharmaceutical Co., Ltd. manufactures and distributes pharmaceuticals. It produces drugs for inflammation, allergy, glaucoma, cataract, and infection. The company was founded on April 9, 1947 and is headquartered in Osaka, Japan.

SemaThera, Inc. engages in research and development in biotechnology. It develops novel inhibitors against semaphorin 3A (SEMA 3A) for prevention and reversal of diabetic macular edema (DME). The company is headquartered in Montreal, Canada.

Deepbiome Therapeutics, Inc. engages in biotechnology operations to develop a new drug discovery platform. The company is headquartered in Cambridge, MA.

KTB Network Co., Ltd. (Venture Capital) is a venture capital subsidiary of Daol Investment Co., Ltd. founded in 1981. KTB Network Co., Ltd. (Venture Capital) is headquartered in Seongnam, South Korea with offices in Shanghai, Palo Alto and Singapore.

GenEdit, Inc. develops gene therapies and gene editing-based therapeutics. Its proprietary nanoparticles applies for the development of CRISPR-based therapeutics and gene therapy products for a range of genetic diseases. The company was founded by Kunwoo Lee, Niren Murthy, and Hyo Min Park in 2016 and is headquartered in Berkeley, CA.